Stock listing
Stuttgart:1ZLB Zai Lab Ltd. Aktie
German listing (Stuttgart) of Zai Lab Ltd. · home listing HKEX:9688
Follow Zai Lab Ltd. into a list and get an email when it puts out news.
Home listing price · HKEX:9688
$16.39 HKD -1.48 (-8.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, HKEX:9688
- Day range
- $16.28 – $17.35 HKDNov 20, 2026
- Volume
- 5.63M sharesNov 20, 2026
- Market cap
- $20.35B HKDAt the close on Nov 20, 2026 · price × 1.24B shares outstanding
- 52-week range
- $12.31 – $21.50 HKDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $111.8M HKDMedian day 5.09M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:9688 · Home | $16.39 HKD | -1.48 (-8.3%) | 5,634,815 | $17.35 | $17.35 | $16.28 | $17.87 | Close on Nov 20, 2026 |
| NASDAQ:ZLAB | $21.03 USD | -0.89 (-4.1%) | 1,442,217 | $20.99 | $21.15 | $20.02 | $21.92 | Close on Nov 20, 2026 |
| Frankfurt:1ZLB | €1.86 EUR | -0.11 (-5.6%) | — | €1.78 | €1.87 | €1.78 | €1.97 | Close on Nov 20, 2026 |
| Frankfurt:1ZL | €18.90 EUR | -0.70 (-3.6%) | — | €18.80 | €18.90 | €18.80 | €19.60 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · HKEX:9688 · HKD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $16.39 | -1.48 | -8.3% | $17.35 | $17.35 | $16.28 | 5,634,815 | |
| $17.87 | -0.90 | -4.8% | $18.79 | $18.79 | $17.65 | 4,677,700 | |
| $18.77 | -0.41 | -2.1% | $18.98 | $19.38 | $18.38 | 5,938,800 | |
| $19.18 | -1.06 | -5.2% | $19.80 | $19.80 | $19.10 | 6,839,300 | |
| $20.24 | -0.78 | -3.7% | $20.82 | $20.82 | $20.02 | 3,443,000 | |
| $21.02 | +0.56 | +2.7% | $20.58 | $21.24 | $20.36 | 4,826,400 | |
| $20.46 | -1.02 | -4.7% | $20.70 | $20.74 | $20.12 | 4,265,500 | |
| $21.48 | +0.52 | +2.5% | $21.06 | $21.50 | $20.90 | 7,042,800 | |
| $20.96 | +2.60 | +14.2% | $19.89 | $21.08 | $19.89 | 10,226,265 | |
| $18.36 | +0.19 | +1.0% | $18.09 | $18.84 | $17.69 | 6,136,930 | |
| $18.17 | +0.16 | +0.9% | $17.80 | $18.33 | $17.70 | 5,093,470 | |
| $18.01 | +1.14 | +6.8% | $16.94 | $18.01 | $16.94 | 5,216,011 | |
| $16.87 | -0.41 | -2.4% | $17.10 | $17.11 | $16.57 | 3,448,060 | |
| $17.28 | -0.09 | -0.5% | $17.41 | $17.52 | $17.00 | 3,600,900 | |
| $17.37 | -0.31 | -1.8% | $17.68 | $17.80 | $17.15 | 2,602,800 | |
| $17.68 | -0.51 | -2.8% | $18.19 | $18.19 | $17.58 | 4,070,800 | |
| $18.19 | +0.01 | +0.1% | $18.24 | $18.51 | $18.06 | 3,718,303 | |
| $18.18 | -0.59 | -3.1% | $18.99 | $19.22 | $18.07 | 5,529,500 | |
| $18.77 | +0.99 | +5.6% | $18.96 | $18.99 | $18.14 | 6,269,500 | |
| $17.78 | -0.06 | -0.3% | $17.56 | $17.96 | $16.71 | 6,642,800 | |
| $17.84 | -1.94 | -9.8% | $18.89 | $19.08 | $17.83 | 4,445,700 | |
| $19.78 | +0.92 | +4.9% | $19.74 | $20.06 | $19.60 | 2,691,100 | |
| $18.86 | +0.26 | +1.4% | $18.70 | $19.10 | $18.70 | 2,340,500 | |
| $18.60 | +0.65 | +3.6% | $18.34 | $18.99 | $18.34 | 4,364,600 | |
| $17.95 | +0.47 | +2.7% | $17.48 | $18.23 | $17.35 | 3,484,500 | |
| $17.48 | -1.51 | -8.0% | $18.26 | $18.26 | $17.29 | 5,712,100 | |
| $18.99 | -0.32 | -1.7% | $19.50 | $19.50 | $18.59 | 3,921,528 | |
| $19.31 | +0.06 | +0.3% | $19.50 | $19.79 | $19.20 | 1,655,500 | |
| $19.25 | +0.06 | +0.3% | $19.30 | $19.35 | $18.93 | 4,911,800 | |
| $19.19 | -0.70 | -3.5% | $20.00 | $20.44 | $19.15 | 6,628,200 | |
| $19.89 | -0.91 | -4.4% | $20.00 | $20.00 | $19.32 | 2,473,840 | |
| $20.80 | +1.73 | +9.1% | $20.40 | $20.94 | $19.98 | 3,233,448 | |
| $19.07 | -0.58 | -3.0% | $19.49 | $19.49 | $18.91 | 1,334,500 | |
| $19.65 | -0.99 | -4.8% | $19.88 | $19.91 | $19.06 | 2,272,610 | |
| $20.64 | +0.26 | +1.3% | $20.48 | $21.00 | $20.26 | 5,544,000 | |
| $20.38 | +0.46 | +2.3% | $20.12 | $20.78 | $20.10 | 5,773,500 | |
| $19.92 | +0.08 | +0.4% | $19.89 | $20.34 | $19.57 | 5,094,600 | |
| $19.84 | -0.14 | -0.7% | $19.70 | $19.92 | $19.53 | 1,463,000 | |
| $19.98 | -1.08 | -5.1% | $20.88 | $20.88 | $19.73 | 4,794,778 | |
| $21.06 | -0.10 | -0.5% | $20.84 | $21.22 | $20.52 | 8,548,722 | |
| $21.16 | +0.22 | +1.1% | $21.00 | $21.16 | $20.60 | 7,554,700 | |
| $20.94 | +0.36 | +1.7% | $20.54 | $21.10 | $19.89 | 8,810,300 | |
| $20.58 | +0.88 | +4.5% | $19.98 | $20.90 | $19.94 | 14,849,300 | |
| $19.70 | +0.33 | +1.7% | $19.71 | $19.72 | $19.35 | 3,019,300 | |
| $19.37 | +0.33 | +1.7% | $19.36 | $19.66 | $19.20 | 5,081,100 | |
| $19.04 | +0.08 | +0.4% | $19.00 | $19.34 | $18.87 | 3,682,100 | |
| $18.96 | +0.02 | +0.1% | $19.00 | $19.09 | $18.59 | 4,856,200 | |
| $18.94 | +0.17 | +0.9% | $18.68 | $19.25 | $18.65 | 12,212,468 | |
| $18.77 | -1.23 | -6.2% | $19.99 | $19.99 | $18.63 | 10,011,700 | |
| $20.00 | 0.00 | 0.0% | $20.24 | $20.38 | $19.87 | 4,651,400 | |
| $20.00 | -0.08 | -0.4% | $20.08 | $20.22 | $19.74 | 2,990,900 | |
| $20.08 | -0.68 | -3.3% | $20.94 | $20.94 | $19.95 | 3,060,400 | |
| $20.76 | -0.30 | -1.4% | $21.00 | $21.40 | $20.60 | 4,331,500 | |
| $21.06 | +0.56 | +2.7% | $20.50 | $21.16 | $20.50 | 9,979,742 | |
| $20.50 | +1.06 | +5.5% | $19.80 | $20.94 | $19.80 | 10,207,929 | |
| $19.44 | -0.36 | -1.8% | $19.80 | $19.94 | $19.30 | 4,217,900 | |
| $19.80 | -0.88 | -4.3% | $20.50 | $20.50 | $19.73 | 6,730,600 | |
| $20.68 | -0.44 | -2.1% | $21.00 | $21.00 | $20.32 | 6,429,400 | |
| $21.12 | +1.02 | +5.1% | $20.32 | $21.22 | $20.10 | 9,544,212 | |
| $20.10 | -0.30 | -1.5% | $20.40 | $20.84 | $20.02 | 6,294,137 | |
| $20.40 | +0.58 | +2.9% | $19.82 | $20.40 | $19.82 | 6,755,613 | |
| $19.82 | -0.52 | -2.6% | $20.30 | $20.60 | $19.69 | 6,392,413 | |
| $20.34 | -0.36 | -1.7% | $20.54 | $20.54 | $19.67 | 8,567,200 | |
| $20.70 | +0.38 | +1.9% | $20.90 | $21.42 | $20.48 | 17,909,900 |
- Ticker
- Stuttgart:1ZLB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Next Day Disclosure Return
Latest earnings call · Nov 5, 2026
Zai Lab (HKEX:9688) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Oct 23, 2026
Investor Presentation (October 2026)
Investor deck · 40 slides
Latest news
Next Day Disclosure Return
Nov 12, 2026
Closed $20.24 (-3.7%) on Nov 13, 2026
Grant of share options and restricted share units
Nov 10, 2026
Closed $20.46 (-4.7%) on Nov 11, 2026
(Revised) monthly return of equity issuer on movements in securities for the month ended 31 October 2026
Nov 9, 2026
Closed $21.48 (+2.5%) on Nov 10, 2026
Overseas regulatory announcement - form 10-Q
Nov 5, 2026
Closed $18.36 (+1.0%) on Nov 6, 2026
Unaudited results for the three and nine months ended September 30, 2026 and corporate updates
Nov 5, 2026
Closed $18.36 (+1.0%) on Nov 6, 2026
Voluntary announcement - closing of the private placement of american depositary shares
Oct 28, 2026
Closed $17.68 (-2.8%) on Oct 29, 2026
Notice of audit committee action
Oct 23, 2026
Closed $18.77 (+5.6%) on Oct 26, 2026
Inside information - update on first data from global Phase 1B clinical trial
Oct 23, 2026
Closed $18.77 (+5.6%) on Oct 26, 2026
Overseas regulatory announcement - form 8-K
Oct 23, 2026
Closed $18.77 (+5.6%) on Oct 26, 2026
Private placement of american depositary shares and issuance of underlying shares under general mandate
Oct 22, 2026
Closed $17.78 (-0.3%) on Oct 23, 2026
Zai Lab Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 32 in the last 12 months · 58 in all · newest Nov 12, 2026 · oldest 2025
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 5, 2026
- Decks
- 11 decks · latest Oct 23, 2026
Where Zai Lab Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:9688 再鼎醫藥 · Home listing | HKEX | Hong Kong | HKD |
| NASDAQ:ZLAB | NASDAQ | United States | USD |
| gettex:1ZL | gettex | Germany | EUR |
| BOATS:ZLAB | BOATS | United States | USD |
| LS Exchange:A3DJSH | LS Exchange | Germany | EUR |
| OTC:ZAILF | OTC | United States | USD |
| Lang & Schwarz:A3DJSH | Lang & Schwarz | Germany | EUR |
| gettex:1ZLB | gettex | Germany | EUR |
| Tradegate:1ZLB | Tradegate | Germany | EUR |
| Frankfurt:1ZLB | Frankfurt | Germany | EUR |
| BMV:ZLABN | BMV | Mexico | MXN |
| Frankfurt:1ZL | Frankfurt | Germany | EUR |
| Tradegate:1ZL | Tradegate | Germany | EUR |
| Munich:1ZLB | Munich | Germany | EUR |
| Dusseldorf:1ZL | Dusseldorf | Germany | EUR |
| Dusseldorf:1ZLB | Dusseldorf | Germany | EUR |
| Lang & Schwarz:A2DX1V | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2DX1V | LS Exchange | Germany | EUR |
| Munich:1ZL | Munich | Germany | EUR |
| Stuttgart:1ZL | Stuttgart | Germany | EUR |
| Stuttgart:1ZLB · This page | Stuttgart | Germany | EUR |
Valuation
EV/sales 4.6× against a median of 15.2×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $15.96B HKD
- P/E
- Loss
- EV/sales
- 4.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.6×
- Gross margin
- 54.7%
- Operating margin
- −63.0%
- Net margin
- −44.9%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Zai Lab Ltd. · HKEX:9688 | US$2.60B | US$2.04B | n/a | 4.6× | n/a | 4.6× | −44.9% | 0.0× | n/a |
| Dyne Therapeutics, Inc. · NASDAQ:DYN | US$2.90B | US$1.97B | n/a | n/a | n/a | 3.1× | n/a | 0.2× | 1.51 |
| Shanghai Junshi Biosciences Co., Ltd. Class A · SSE:688180 | US$2.88B | US$3.00B | n/a | 8.0× | n/a | 3.2× | −35.0% | 0.7× | n/a |
| SELLAS Life Sciences Group, Inc. · NASDAQ:SLS | US$2.78B | US$2.65B | n/a | n/a | n/a | 21.1× | n/a | 0.0× | 2.19 |
| HLB Co., Ltd. · KRX:028300 | US$2.67B | US$2.67B | n/a | 36.9× | n/a | 10.4× | −219.1% | 0.2× | n/a |
| Celcuity Inc. · NASDAQ:CELC | US$2.62B | US$1.98B | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Xencor, Inc. · NASDAQ:XNCR | US$2.50B | US$2.16B | n/a | 10.8× | n/a | 4.5× | −58.8% | 0.1× | 1.21 |
| IDEAYA Biosciences, Inc. · NASDAQ:IDYA | US$2.47B | US$1.66B | n/a | 45.5× | n/a | 2.3× | n/a | 0.0× | 0.96 |
| MBX Biosciences, Inc. · NASDAQ:MBX | US$2.46B | US$1.98B | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 1.30 |
| Almirall SA · BME:ALM | US$2.45B | US$2.46B | 31.1× | 1.6× | 7.3× | 1.5× | 5.1% | 0.2× | n/a |
| Keymed Biosciences, Inc. · HKEX:2162 | US$2.43B | US$2.04B | n/a | 19.6× | n/a | 4.0× | −73.0% | 0.2× | n/a |
| Median of the others | US$2.56B | US$2.10B | 31.1× | 15.2× | 7.3× | 4.0× | −58.8% | 0.2× | 1.25 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.03 HKD · Analysts' mean
- EPS, year to Dec 2026
- -0.20 · 2 analysts
- Revenue, year to Dec 2026
- 439.1M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Samantha Du | Founder, Chairperson and Chief Executive Officer |
| Yajing Chen | Chief Financial Officer |
| Rafael G. Amado | President, Head of Global Research and Development |
| F. Ty Edmondson | Chief Legal Officer and Corporate Secretary |
| Cyan Liu | Investor Relations |
| Shan He | Senior Vice President, Chief Business Officer |
Board
| Director | Role |
|---|---|
| Samantha Du | Founder, Chairperson and Chief Executive Officer |
| John D. Diekman | Board Member |
| Lonnie Moulder | Board Member |
| Michel Vounatsos | Board Member |
| Nisa Leung | Board Member |
| Peter Wirth | Board Member |
| Richard Gaynor | Board Member |
| Scott Morrison | Board Member |
| William Lis | Board Member |
Events
Calls
| Call | When | Status |
|---|---|---|
| Zai Lab (HKEX:9688) Q3 2026 Earnings Call | Thu, Nov 05, 2026 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q1 2026 Earnings Call | Thu, May 07, 2026 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q4 2025 Earnings Call | Thu, Feb 26, 2026 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 8:00 PM ET | Replay |
All 22 calls
| Call | When | Status |
|---|---|---|
| Zai Lab (HKEX:9688) Q1 2024 Earnings Call | Thu, May 09, 2024 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q4 2023 Earnings Call | Wed, Feb 28, 2024 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q3 2023 Earnings Call | Wed, Nov 08, 2023 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q2 2023 Earnings Call | Tue, Aug 08, 2023 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q1 2023 Earnings Call | Wed, May 10, 2023 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q4 2022 Earnings Call | Thu, Mar 02, 2023 · 9:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q3 2022 Earnings Call | Thu, Nov 10, 2022 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q2 2022 Earnings Call | Wed, Aug 10, 2022 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q1 2022 Earnings Call | Wed, May 11, 2022 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q4 2021 Earnings Call | Wed, Mar 02, 2022 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q3 2021 Earnings Call | Wed, Nov 10, 2021 · 8:00 AM ET | Replay |
| Zai Lab (HKEX:9688) Q2 2021 Earnings Call | Tue, Aug 10, 2021 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | +0.9% |
| Q2 2026 | Aug 6, 2026 · Before open | +0.8% |
| Q1 2026 | May 6, 2026 · Before open | −1.7% |
| Q4 2025 | Feb 26, 2026 · Before open | −3.1% |
| Q3 2025 | Nov 6, 2025 · Before open | −2.2% |
| Q2 2025 | Aug 7, 2025 · Before open | −2.0% |
| Q1 2025 | May 8, 2025 · Before open | −1.3% |
| Q4 2024 | Feb 27, 2025 · Before open | +4.9% |
| Q3 2024 | Nov 12, 2024 · Before open | −1.2% |
| Q2 2024 | Aug 6, 2024 · After close | +6.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | +20.8% |
| Q4 2023 | Feb 27, 2024 · After close | −2.3% |
| Q3 2023 | Nov 7, 2023 · After close | +4.3% |
| Q2 2023 | Aug 7, 2023 · After close | −3.1% |
| Q1 2023 | May 9, 2023 · After close | +1.4% |
| Q4 2022 | Mar 1, 2023 · After close | +1.7% |
| Q3 2022 | Nov 9, 2022 · After close | −0.9% |
| Q2 2022 | Aug 9, 2022 · After close | −6.4% |
| Q1 2022 | May 10, 2022 · After close | +12.9% |
| Q4 2021 | Mar 2, 2022 · Before open | −9.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 40 slides | Oct 23, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 19 slides | Aug 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 17 slides | May 7, 2026 |
| Technical Presentation (April 2026) | Technical | 42 slides | Apr 20, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference 2026 | Conference | 22 slides | January 2026 |
| Q3 2025 Earnings Presentation | Earnings | 22 slides | Nov 6, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 40 slides | Aug 7, 2025 |
| Technical Presentation (November 2021) | Technical | 16 slides | November 2021 |
| Technical Presentation (November 2021) | Technical | 17 slides | November 2021 |
| Technical Presentation (2020) | Technical | 17 slides | 2020 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| JP Morgan Healthcare Conference 2018 | Conference | 20 slides | Jan 8, 2018 |
Financings
| Raise | Date |
|---|---|
| Private placement of new ordinary shares Closed: HK$17.28 a share | Nov 9, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 an ADS on Sep 20, 2017.
- Price
- US$18.00 an ADS
- ADSs offered
- 8,333,333 American depositary shares
- Offering size
- US$150 million
- Underwriters' option
- Up to 1,250,000 more ADSs
- Underwriters
- J.P. Morgan, Citigroup, Leerink Partners · In the order on the cover
- ADSs delivered
- On or about Sep 22, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 31, 2017 |
| Filed publicly | Aug 15, 2017 |
| Amended 3 times | Newest Sep 20, 2017 |
| Shares registered with an exchange | Sep 14, 2017 |
| Declared effective by the SEC | Sep 20, 2017 |
| Final prospectus, with the price | Sep 21, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 21, 2017 |
| EFFECT · Notice that a registration is effective | Sep 20, 2017 |
| F-1MEF · Registration of more shares for the same offering | Sep 20, 2017 |
| F-1/A · Registration statement, amended | Sep 20, 2017 |
| CORRESP · Letter to the SEC | Sep 15, 2017 |
| CORRESP · Letter to the SEC | Sep 15, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 14, 2017 |
| F-1/A · Registration statement, amended | Sep 1, 2017 |
| F-1/A · Registration statement, amended | Aug 23, 2017 |
| CORRESP · Letter to the SEC | Aug 22, 2017 |
All 20 filings
| Filing | Filed |
|---|---|
| F-1 · Registration statement | Aug 15, 2017 |
| DRS/A · Draft registration statement, amended | Aug 2, 2017 |
| DRSLTR · Letter to the SEC with a draft | Aug 1, 2017 |
| UPLOAD · Letter from the SEC | Jul 21, 2017 |
| DRS/A · Draft registration statement, amended | Jul 11, 2017 |
| DRSLTR · Letter to the SEC with a draft | Jul 10, 2017 |
| UPLOAD · Letter from the SEC | Jun 28, 2017 |
| DRSLTR · Letter to the SEC with a draft | Jun 27, 2017 |
| DRS/A · Draft registration statement, amended | Jun 27, 2017 |
| DRS · Draft registration statement | May 31, 2017 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 21, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 460.2M | 399.0M | 266.7M | 215.0M | 144.3M | 49.0M | 13.0M | 129.0K | ||
| Cost of revenue | 190.5M | 147.1M | 95.8M | 74.0M | 52.2M | 16.7M | 3.75M | 43.0K | ||
| Gross profit | 269.6M | 251.9M | 170.9M | 141.0M | 92.1M | 32.2M | 9.24M | 85.9K | ||
| Research and development | 220.9M | 234.5M | 265.9M | 286.4M | 573.3M | 222.7M | 142.2M | 120.3M | 39.3M | 32.1M |
| Selling, general and administrative | 277.6M | 298.7M | 281.6M | 259.0M | 218.8M | 111.3M | 70.2M | 21.6M | 12.0M | 6.38M |
| Operating income | -229.4M | -282.1M | -366.6M | -404.4M | -700.1M | -301.8M | -203.2M | -141.8M | -51.4M | -38.5M |
| Depreciation and amortization | 15.0M | 11.9M | 9.03M | 8.23M | 6.49M | 4.64M | 3.77M | 1.65M | 548.0K | 198.2K |
| EBITDA | -214.4M | -270.3M | -357.5M | -396.1M | -693.6M | -297.2M | -199.4M | -140.1M | -50.8M | -38.3M |
| Interest expense | 5.21M | 2.25M | 0 | 0 | 0 | 181.0K | 293.0K | 40.0K | ||
| Income before tax | -178.5M | -257.1M | -334.6M | -443.3M | -704.5M | -268.9M | -195.1M | -139.1M | -50.4M | -37.5M |
| Income tax | -2.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income | -175.5M | -257.1M | -334.6M | -443.3M | -704.5M | -268.9M | -195.1M | -139.1M | -50.4M | -37.5M |
| Earnings per share, basic | -0.16 | -0.26 | -0.35 | -0.46 | -0.76 | -0.35 | -3.03 | -2.64 | -2.32 | -3.97 |
| Earnings per share, diluted | -0.16 | -0.26 | -0.35 | -0.46 | -0.76 | -0.35 | -3.03 | -2.64 | -2.32 | -3.97 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 679.6M | 449.7M | 790.2M | 1.01B | 964.1M | 442.1M | 75.9M | 63.0M | 229.7M | 83.9M |
| Short-term investments | 10.0M | 330.0M | 16.3M | 0 | 445.0M | 744.7M | 200.0M | 200.3M | ||
| Receivables | 106.1M | 85.2M | 59.2M | 40.0M | 47.5M | 5.17M | 3.79M | 90.0K | ||
| Inventory | 74.7M | 39.9M | 44.8M | 31.6M | 19.0M | 13.1M | 6.00M | 4.00K | ||
| Current assets | 1.02B | 1.05B | 939.6M | 1.12B | 1.50B | 1.22B | 292.5M | 269.1M | 230.6M | 84.1M |
| Property, plant and equipment | 47.4M | 48.0M | 53.7M | 57.9M | 43.1M | 29.2M | 21.4M | 20.5M | 11.9M | 1.25M |
| Total assets | 1.17B | 1.19B | 1.04B | 1.22B | 1.61B | 1.30B | 355.2M | 302.0M | 249.6M | 88.9M |
| Accounts payable | 141.6M | 100.9M | 113.0M | 66.0M | 126.2M | 62.6M | 22.7M | 37.4M | 8.97M | 523.3K |
| Current liabilities | 416.2M | 299.4M | 203.1M | 139.8M | 192.9M | 98.0M | 46.6M | 48.8M | 12.1M | 5.17M |
| Total liabilities | 456.9M | 344.9M | 240.2M | 174.5M | 230.0M | 128.3M | 60.5M | 50.9M | 14.5M | 5.95M |
| Shareholders' equity | 715.5M | 840.9M | 796.1M | 1.05B | 1.38B | 1.17B | 294.7M | 251.1M | 235.2M | -51.6M |
| Shares outstanding | 1.11B | 1.08B | 972.2M | 960.2M | 955.0M | 87.8M | 68.2M | 58.0M | 49.9M | 9.66M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -150.8M | -214.9M | -198.2M | -367.6M | -549.2M | -216.1M | -191.0M | -97.5M | -32.4M | -32.2M |
| Capital spending | -8.10M | -5.66M | -7.21M | -24.6M | -18.3M | -10.1M | -6.04M | -10.0M | -9.10M | -2.22M |
| Free cash flow | -158.9M | -220.5M | -205.4M | -392.2M | -567.5M | -226.2M | -197.0M | -107.6M | -41.5M | -34.4M |
| Cash from investing | 307.9M | -375.2M | -10.8M | 420.0M | 250.0M | -554.8M | -14.9M | -212.6M | -10.4M | -2.73M |
| Cash from financing | 72.4M | 349.9M | -6.43M | -1.73M | 820.2M | 1.13B | 219.3M | 144.1M | 187.9M | 106.2M |
| Change in cash | 229.9M | -240.5M | -218.0M | 44.4M | 522.0M | 366.4M | 13.5M | -166.7M | 145.7M | 70.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| Next Day Disclosure Return | Nov 12, 2026 | Next day disclosure return | HKEX |
| GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | Nov 10, 2026 | Other filings | HKEX |
| D | Nov 9, 2026 | Other filings | SEC |
| (REVISED) MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2026 | Nov 9, 2026 | Monthly return | HKEX |
| MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2026 | Nov 5, 2026 | Monthly return | HKEX |
| OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q | Nov 5, 2026 | Quarterly report | HKEX |
| UNAUDITED RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND CORPORATE UPDATES | Nov 5, 2026 | Results | HKEX |
Show 200 filings
This page holds 200 of 757 filings. Open Filings
Cap table
Built by 6ix from Zai Lab Ltd.’s releases · as of Nov 9, 2026
- Common shares
- 1,241,451,110
- Fully diluted
- 1,241,451,110
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,241,451,110 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,241,451,110 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Leon O Moulder Jr Other companies: Zenas BioPharma, Inc. (See Remarks, Director · Since at least Sep 12, 2024); Dianthus Therapeutics, Inc. (Director · Sep 11, 2023 – May 23, 2024 · Past); Trevena, Inc. (Director · May 16, 2018 – Jun 15, 2023 · Past); Tesaro Inc (Chief Executive Officer, Director · Mar 1, 2018 – Jan 22, 2019 · Past) | Director · Since at least Jan 1, 2021 |
| Alan Sandler Other companies: Revolution Medicines, Inc. (Chief Development Officer · Since at least Nov 5, 2025); ALX Oncology Holdings Inc. (Director · Since at least Aug 5, 2024); Elevation Oncology Inc (Director · Since at least Feb 29, 2024) | Head of Global Dev., Oncology · Jan 1, 2021 – Jun 25, 2022 · Past |
| Rafael G. Amado Other companies: Poseida Therapeutics Inc (Director · Apr 13, 2023 – Jan 8, 2025 · Past); Allogene Therapeutics, Inc. (EVP of R&D · Sep 3, 2019 – Oct 7, 2022 · Past); Adaptimmune Therapeutics PLC (President, R&D · Jan 1, 2016 – Aug 6, 2019 · Past) | President, Head of Global Research and Development · Since at least Dec 30, 2022 |
| William Lis Other companies: Jasper Therapeutics, Inc. (Director · Sep 24, 2021 – Oct 13, 2023 · Past); Eidos Therapeutics Inc (Director · Dec 4, 2018 – Jan 26, 2021 · Past); Portola Pharmaceuticals Inc (Chief Executive Officer, Director · May 21, 2013 – Jul 28, 2018 · Past) | Board Member · Since at least Jan 1, 2021 |
| Michel Vounatsos Other companies: Revvity, Inc. (Director · Since at least Mar 1, 2020); Biogen Inc. (Director · Apr 18, 2016 – Nov 5, 2026 · Past) | Director · Since at least Jan 7, 2023 |
| Peter Wirth Other companies: Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Oct 14, 2022 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 1, 2022 – Jun 5, 2024 · Past) | Director · Since at least Dec 8, 2021 |
| Scott Morrison Other companies: IDEAYA Biosciences, Inc. (Director | Partner, Ernst & Young (retired) · Since at least Nov 4, 2026); Tarsus Pharmaceuticals, Inc. (Director · Since at least Jun 12, 2026) | Board Member · Since at least Jun 17, 2026 |
| John D. Diekman Other companies: IDEAYA Biosciences, Inc. (Director · May 22, 2019 – Sep 24, 2019 · Past) | Board Member · Since at least Jan 1, 2021 |
| Lonnie Moulder Other companies: Zenas BioPharma, Inc. (Chief Executive Officer and Chairman of the Board of Directors · Since at least Aug 13, 2026) | Board Member · Since at least Nov 5, 2026 |
| Richard B. Gaynor Other companies: Alkermes plc (Director · Since at least Dec 2, 2020) | Director · Since at least Nov 19, 2021 |
All 22 people
| Person | Seat |
|---|---|
| Cyan Liu | Investor Relations · Since at least Jul 22, 2026 |
| Frazor Titus Edmondson III | Chief Legal Officer · Since at least Jan 1, 2021 |
| F. Ty Edmondson | Chief Legal Officer and Corporate Secretary · Since at least Nov 5, 2026 |
| Joshua L Smiley | See Remarks · Since at least Aug 1, 2022 |
| Kai-Xian Chen | Director · Jan 1, 2021 – Dec 31, 2024 · Past |
| Nisa Leung | Board Member · Since at least Jun 22, 2026 |
| Samantha Du | Founder, Chairperson and Chief Executive Officer · Since at least May 7, 2026 |
| Shan He | Senior Vice President, Chief Business Officer · Since at least Nov 5, 2026 |
| William Ki Chul Cho | Chief Financial Officer · Jan 1, 2021 – Apr 3, 2023 · Past |
| Yajing Chen | Chief Financial Officer · Since at least Apr 1, 2026 |
| Ying Du | Chairperson & CEO, Director · Since at least Jan 1, 2021 |
| Yizhe Wang | Operating Partner · Since at least Apr 27, 2026 |
Log in to ask 6ix AI your own questions about Zai Lab Ltd.